List of Poster Presentations
A DOUBLE JEOPARDY: THROMBOTIC THROMBOCYTOPENIC PURPURA IN SYSTEMIC MASTOCYTOSIS – A RARE BUT LETHAL CONUNDRUM
Sidar Çöpür, T. Tan, S. Bozdag, U. Ure, E. Osmanbasoglu, M. Akay
Koc University School of Medicine Internal Medicine and Hematology Departments
A PROSPECTIVE, OBSERVATIONAL STUDY EXAMINING THE SAFETY AND EFFECTIVENESS OF THALIDOMIDE AND HYDROXYUREA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA
Ali Kashif, Nisar Huda, Naeem IIyad, Saqib Hussain Ansari
Department of Pharmacy Practice, Dow University of Health Sciences; Department of Hematology/Oncology, The Children’s Hospital, Karachi, Pakistan
ACCURACY OF ULTRASOUND-GUIDED CORE NEEDLE BIOPSY FOR THE EVALUATION OF LYMPHADENOPATHIES SUSPECTED OF LYMPHOMA. THE EXPERIENCE OF THE REGGIO EMILIA CENTER
G. Torsello1|2, V. Maccabruni3, B. Marani3, F. Merli2, S. Luminari2, M. Zanelli4, R. Valli4, G. Menozzi3
1Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia; 2Hematology Unit, Azienda USLIRCCS di Reggio Emilia; 3Diagnostic and Interventional Ultrasound Center, Azienda USL-IRCCS di Reggio Emilia; 4Pathology Unit, Azienda USL- IRCCS di Reggio Emilia
ADHERENCE TO CLINICAL PROTOCOLS FOR MANAGING FEBRILE NEUTROPENIA IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Kashif Ali, Azizullah Dhiloo, Ayesha Rafiq
Dow University of Health Sciences
BELANTAMAB MAFODOTIN+BORTEZOMIB+DEXAMETHASONE (BVD) VS DARATUMUMAB+VD (DVD) IN RRMM: UPDATES ON OVERALL SURVIVAL (OS) AND EFFICACY IN DREAMM-7
C. Cerchione1, V. Hungria2, P. Robak3, M. Hus4, V. Zherebtsova5, C. Ward6, P. Ho7, R. Hajek8, K. Kim9, S. Grosicki10, H. Sia11, A. Bryant12, M. Lacerda13, G. Martinez14, A. Balarí15, I. Sandhu16, P. Ganly17, M. Dimopoulos18, C. Fu19, M. Garg20, A-O. Abdallah21, M. Gatt22, A. Oriol23, M. Cavo24, R. Rifkin25, T. Fujisaki26, M. Mielnik4, N. Pirooz27, J. Lee28, A. Mckeown29, R. Rogers27, H. Baig30, L. Eccersley28, S. Roy-Ghanta27, J. Opalinska27, M. Mateos31
1Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST IRCCS; 2Clinica São Germano; 3Medical University of Lodz; 4Medical University of Lublin; 5Gorodskaya Klinicheskaya Bol’nitsa Im. S. p. Botkina; 6Royal North Shore Hospital; 7Royal Prince Alfred Hospital; 8University Hospital Ostrava and University of Ostrava; 9Sungkyunkwan University, Samsung Medical Center; 10Medical University of Silesia; 11Pindara Private Hospital; 12Liverpool Hospital; 13Universidade da Região de Joinville and Centro de Hematologia e Oncologia; 14Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo; 15Institut Català d’Oncologia-L’Hospitalet L. -Barcelona; 16Cross Cancer Institute; 17Christchurch Hospital; 18Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens; 19The First Affiliated Hospital of Soochow University; 20University Hospitals of Leicester NHS Trust; 21University of Kansas Cancer Center; 22Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem; 23Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol; 24IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 25Rocky Mountain Cancer Centers – Denver -Midtown; 26Matsuyama Red Cross Hospital; 27GSK (Upper Providence); 28GSK (London); 29GSK (Stevenage); 30GSK (Mississauga); 31Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USALCSIC)
CHRONIC KIDNEY DYSFUNCTION FOLLOWING ALLOGENEIC TRANSPLANT: A RARE CASE OF RENAL GVHD AND THROMBOTIC MICROANGIOPATHY
T. Tan, A. U. Topçu, S. C. Bozdağ, D. E. Baydar
Koc University Hospital
CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL
N. Maher (1|2), R. Moia (1), M. Almasri (1), E. Genuardi (3), M. Drandi (3), C. Cosentino (1), R. Soscia (4), Gm. Assanto (4), A. Tucci (5), C. Boccomini (6), J. Olivieri (8), L. Arcaini (9|10), F. Ballerini (11), F. Cavallo (12), B. Puccini (13), C. Patti (14), C. Stelitano (15), A. Pulsoni (16), A. Santoro (17), A. Pinto (18), Vr. Zilioli (19), L. Marcheselli (20), S. Ciavarella (21), R. Bomben
(22), S. Galimberti (23), I. Del Giudice (4), M. Ladetto (2), G. Gaidano (1), S. Luminari (24), S. Ferrero (3)
1. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2. Department of Translational Medicine, SCDU Ematologia AO SS Antonio e Biagio E Cesare Arrigo, Università del Piemonte Orientale; 3. Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino; 4. Hematology, Department of Translational and Precision Medicine, ‘Sapienza’ University; 5. Division of Hematology, ASST Spedali Civili; 6. Hematology Division, A. O. U. Città della Salute e della Scienza di Torino; 7. Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori; 8. Hematology and SCT Unit, Azienda Sanitaria Universitaria Integrata Santa Maria della Misericordia; 9. Division of Hematology, Istituto scientifico San Matteo, University of Pavia; 10. IRCCS Ospedale Policlinico San Martino; 11. Division of Hematology, University Hospital A. O. U. “Città della Salute e della Scienza”; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin; 12. Hematology Unit, Careggi University Hospital; 13. Oncohematology Azienda Ospedali Riuniti Villa Sofia-V. Cervello Palermo; 14. Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Ematologia Reggio Calabria; 15. Department of Hematology, SM Goretti Hospital, University Polo Pontino; 16. IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology; 17. Hematology- Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’; 18. ASST Grande Ospedale Metropolitano Niguarda; 19. Uffici Studi Fondazione Italiana Linfomi; 20. Hematology and Cell Therapy Unit, IRCCS Istituto Tumori ‘Giovanni Paolo II’; 21. Centro di Riferimento Oncologico di Aviano; 22. Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa; 23. Ematologia, Azienda Unità Sanitaria Locale – IRCCS Reggio Emilia
CONNECTING SENESCENCE AND METABOLIC CHANGES IN MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES
G. N. Conti[1], D. Calvo[2], S. Giallongo[3], G. Lazzarino[4], F. Bellia[1], A. Duminuco[2], E. La Spina[1], M. Aguennouz[5], F. Polito[6], G. Testa[7], A. Romano[8], F. Di Raimondo[8], D. Tibullo[1], G. A. Palumbo[9], C. Giallongo[9]
[1]. Department of Biomedical and Biotechnological Sciences, University of Catania; [2]. Hematology Unit with BMT, A. O. U. Policlinico “G. Rodolico-San Marco”, Catania, Italy; [3]. Department of Medicine and Surgery, University of Enna (Kore); [4]. UniCamillus-Saint Camillus International University of Health and Medical Sciences; [5]. Department of Neurology, University of Messina; [6]. Department of Clinical and Experimental Medicine, University of Messina; [7]. Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, A. O. U. P. Policlinico Rodolico-San Marco, University of Catania;[8]. Department of General Surgery and Medical-Surgical Specialties, University of Catania; [9]. Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, Division of Hematology, University of Catania
DEXAMETHASONE AND DARATUMUMAB IMPAIR T-CELL MEDIATED KILLING IN MULTIPLE MYELOMA: IMPLICATIONS FOR SEQUENTIAL THERAPIES
Ilaria Dulcamare[1], S. Marino[2], N. L. Parrinello[2], G. Scandura[1], E. La Spina[3], D. Cambria[2][4], C. Giallongo[5], D. Tibullo[3], A. Romano [6][2] And F. Di Raimondo [6][2]
1. Department of Clinical and Experimental Medicine; 2. AOU Policlinico G. Rodolico, Division of Hematology; 3. Department of Biomedical and Biotechnological Sciences; 4. AUO Policlinico Paolo Giaccone; 5. Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”; 6. Department of General Surgery and Medical-Surgical Specialties
EFFECTIVENESS ASSESSMENT OF A TRBC1-DIRECTED CHIMERIC ANTIGEN RECEPTOR AGAINST T ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA
A. De Lucia*1,2, F. Nicolini*1, A. Ottaviani*3, C. Quintarelli3, B. De Angelis3, L. Mazzotti1,2, A. Gaimari1,2, C. Cerchione1, F. Locatelli3, G. Martinelli1, M. Mazza1
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Department of Biomedical and Neuromotor Sciences, Cell Signalling Laboratory, University of Bologna; Department Onco-Hematology, Cell and Gene Therapy, IRCCS, Bambino Gesù Children’s Hospital
FREQUENCY OF AUTOIMMUNE HAEMOLYTIC ANAEMIA IN CHRONIC LYMPHOCYTIC LEUKAEMIA
Aurelian Udristioiu
Titu Maiorescu University of Bucharest, Faculty of Medicine, General Assistance, Targu Jiu, Romania
IMPACT OF A GLOBAL DIGITAL PLATFORM IN COMBATING MISINFORMATION THROUGH DIGITAL EDUCATION IN HEMATOLOGY ONCOLOGY
V. Cortiana1, A. Hashim2, G. P. Menon2, M. Joshi2, M. Balasubramanian2, H. S. Coloma3, A. Van De Kieft4, H. Chorya5, R. H. Abbas2, J. Ghazal6, C. H. Park7, Y. Leyfman8
1. University of Bologna; 2. Tbilisi State Medical University; 3. . Harvard University; 4. Cornell University; 5. Baroda Medical College; 6. Mattawan High School; 7. Norton Cancer Institute; 8. Icahn School of Medicine at Mount Sinai
INBORN ERRORS OF IMMUNITY MEET WITH REAL-LIFE CLINICAL SETTINGS: A SINGLE CENTRE EXPERIENCE OF GENE SEQUENCING OF HUMORAL IMMUNE DEFECTS
A Andriano 1, V Desantis 1, C Marasco 2, A Marzollo 3, S Bresolin 4, N Resta 1, L Di Marzo 1, F Pappagallo 2, A Mascolo 2, I C Caradonna 1, S D’amore 1, A Vacca 1, A G Solimando 1
1 University of Bari Aldo Moro, 2 Azienda Ospedaliera Universitaria Policlinico di Bari, 3 Padua University Hospital, 4 Istituto di Ricerca Pediatrica Foundation – Città della Speranza
INTEGRATION OF [18F]FDG-PET RADIOMICS WITH LIQUID BIOPSY IMPROVES OUTCOME PREDICTION IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA
R. Dondolin1, F. Garrou2, M. Almasri1, L. Terzi Di Bergamo3, C. Cosentino1, A. Bruscaggin3, M. Salehi3, D. Talotta1, R. Bruna1, G.M. Rivolta1, M. Bellia1, J. Nabki1, B. Al Deeban1, L. Cividini1, S. Mouhssine1, N. Maher1, J. Ghanej1, F. Maiellaro1, A. Andorno4, F. Mercalli4, M. Leutner5, A. Lorenzi6, A. M. Mahmoud1, W. Al Essa1, N. M. Diop1, E. Secomandi1, C. Deambrogi1, S. Rasi1, R. L. Boldorini4, M. Gentile7, G. A. Palumbo8, V. Gattei9, R. Foà10, D. Rossi3, G. M. Sacchetti2, R. Moia1, G. Gaidano1
1. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2. Division of Nuclear Medicine, AOU Maggiore della Carità; 3. Laboratory of Experimental Hematology, Institute of Oncology Research; 4. Division of Pathology, Department of Health Sciences, Università del Piemonte Orientale; 5. Division of Pathology, Azienda Sanitaria Locale del VCO; 6. Division of Hematology, Azienda Sanitaria Locale del VCO; 7. Hematology Unit AO of Cosenza; 8. Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G. F. Ingrassia”, University of Catania; 9. Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS; 10. Hematology, Department of Translational and Precision Medicine, ‘Sapienza’ University
LIPID DYSREGULATION AND ANTI-BCMA IMMUNOTHERAPY RESISTANCE IN MULTIPLE MYELOMA
E. La Spina 1, A. Romano 28, C. Giallogno 3, G. Scandura 2, S. Cortellino 4, L. Longhitano 1, S. Giallongo 9, T. Zuppelli 10, Gn. Conti 1, J. Ferrigno 1, Sp. Lombardo 1, E. Tropea 1, M. Mecca 4, S. Picerno 4, A. Amoresano 5, S. Serpico 5, A. Sgambato 6, F. Torricelli 7, N. Puccio 7, N. Parrinello 8, G. Li Volti 1, G. A. Palumbo 3, D. Tibullo 1, F. Di Raimondo 28.
1. Department of Biomedical and Biotechnological Sciences, University of Catania, 2. Department of General Surgery and Medical-Surgical Specialties, University of Catania, 3. Department of Medical, Surgical Sciences and Advanced Technologies G. F. Ingrassia University of Catania, 4. Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 5. Department of Chemical Sciences, University of Naples Federico II, 6. Catholic University of Rome, 7. IRCCS Institute for Advanced Technologies and Care Models in Oncology, 8. Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, 9. Department of Medicine and Surgery, University of Enna (Kore)
PERFORMANCE OF APHERESIS TECHNOLOGIES IN HEMATOPOIETIC STEM CELL COLLECTION: A COMPARATIVE ANALYSIS
T. Tan, A. U. Topçu, N. S. Çiçek, T. Akan, E. Osmanbaşoğlu, S. C. Bozdağ, Ü. B. Üre, O. M. Akay
Koc University Hospital
PREDICTIVE VALUE OF THE EASIX SCORE FOR VASCULAR EVENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
T. Tan, A. U. Topçu, E. Osmanbaşoğlu, Ü. B. Üre, S. C. Bozdağ, O. M. Akay
Koç University Hospital
PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
S. Mouhssine (1)*, C. Cosentino (1)*, M. Almasri (1), I. Romano (2,3), L. Terzi Di Bergamo (2), J. Nabki (1), L. Cividini (1), B. Al Deeban (1), F. Maiellaro (1), Mr. Nawabi (1), A. Gaglio (4), F. Perutelli (5), V. Griggio (5), R. Dondolin (1), M. Bellia (1), S. Rasi (1), E. Secomandi (1), S. Kogila (1), J. Ghanej (1), N. Maher (1,6), Nm Diop (1), M. Lazzaro (1), E. Albi (7), C. Vitale (8), L. Scarfo (9,10), P. Ghia (9,10), M. Coscia (8,11), V. Gattei (4), A. Zucchetto (4), D. Rossi (2), G. Gaidano (1), R. Moia (1);
* Equally Contributed
1. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2. Institute of Oncology Research, Laboratory of Experimental Hematology; 3. Swiss Group for Clinical Cancer Research (SAKK); 4. Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS; 5. A. O. U. Città della Salute e della Scienza di Torino e Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino; 6. Department of Translational Medicine, SCDU Ematologia AOU SS Antonio e Biagio e Cesare Arrigo, Università del Piemonte Orientale; 7. Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; 8. Division of Hematology, A. O. U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino; 9. Università Vita Salute San Raffaele; 10. Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milano, Italy; 11. Hematology Division, ASST Sette Laghi, Ospedale di Circolo
ROPEGINTERFERON IN A PATIENT WITH POLYCYTHEMIA VERA AND BILATERAL ANKLE ULCERS
M. S. Aydin, E. Isleyen, F. Ceran, S. Dagdas, G. Ozet
Department of Hematology and Bone Marrow Transplantation, Ankara Bilkent City Hospital, Ankara, Turkey
SIGNIFICANCE ESTIMATION OF NK CELLS IN HEMATOLOGY
Jurisic V
University of Kragujevac, Faculty of Medical Sciences, Serbia
THE INFLAMMASOME NEGATIVELY DRIVES HEME OXYGENASE 1 ACTIVATION REGULATING BONE MARROW FIBROSIS IN PRIMARY MYELOFIBROSIS
Calvo [1], G. N. Conti [1], A. Duminuco [4], E. Tropea [1], A. Romano [4], Di Raimondo[4], G. Li Volti [1], G. A. Palumbo, [3]. N Vicaro [1], D. Tibullo [1]
[1] Department of Biomedical e Biotechnological sciences, University of Catania; [2] Department of Medicine and Surgery, University of Enna (Kore); [3] Department of Medical, Surgical Sciences and Advanced Technologies G. F. Ingrassia University of Catania; [4] Department of General Surgery and Medical-Surgical Specialties
TRANSGELIN-2 AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL DAMAGE
R Magdy Said, N. Ismaiel, R. Zakaria, D. Fahmy N. Ibrahim
Ain Shams University Hospital, Hematology Department and BMT Unit
UNDERSTANDING THE EXPERIENCE OF CANCER PATIENTS UNDERGOING PHASE 1 CLINICAL TRIALS: A PHENOMENOLOGICAL STUDY
Sabrina Marietti1, Stefano Benini2, Monica Garaffoni1, Eleonora Spada1, Federica Beniamino1, Luca Ballanti1, Michela Rustignoli1, Marina Bragagni 1, Sabrina Prati 1, Anita Zeneli1
1 Istituto Istituto Romagnolo per lo studio dei tumori “Dino Amadori” IRST IRCCS – Meldola; 2 Azienda USL di Bologna
UPDATED CLINICO-BIOLOGICAL PROFILE AND TREATMENT OUTCOMES OF CHRONIC LYMPHOCYTIC LEUKEMIA
V. Musteata1|2, V. Cepraga 1, L. Musteata 1, N. Sghibneva-Bobeico 1|2, D. Urescu 1|2, I. Cebanu 1|2
1 Discipline of Hematology, „Nicolae Testemitanu” State University of Medicine and Pharmacy, 2 Institute of Oncology
VENETOCLAX PLUS HYPOMETHYLATING AGENT COMBINATION AS EFFECTIVE BRIDGE THERAPY TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML PATIENTS: A SUB-ANALYSIS OF THE AVALON STUDY
E. Todisco1, E. Petracci2, F. Pavesi1, I. Lotesoriere1, S. Gatani1, C. Zingaretti2, M. B. Giannini3, P. Zappasodi4, C. Papayannidis5, C. Vetro6, A. Cignetti7, F. Vincenzo8, E. Borlenghi9, N. Fracchiolla10, L. Facchini11, L. Maurillo12, E. Audisio13, I. Manfra14, M. Bernardi15, F. Ferrara16, F. Lanza17, C. Selleri18, F. Lussana19, F. Gigli20, L. Castagna21, C. Cerchione 22, G. Martinelli23
1. Hematology Unit, ASST Valle Olona; 2. Biostatistics and Clinical Trial Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori; 3. Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori; 4. Hematology Unit, University of Pavia/IRCCS Policlinico San Matteo Foundation; 5. Seragnoli Hematology Institute, IRCCS Azienda Ospedaliero-Universitaria di Bologna; 6. Hematology Unit, Azienda Ospedaliera dell’Alto Adige, Ospedale di Bolzano; 7. Hematology Unit, AO Ordine Mauriziano; 8. Hematology Unit, Ospedale “Vito Fazzi”; 9. Hematology Unit, ASST Spedali Civili; 10. Hematology Unit, University of Milan/IRCCS Ca’ Granda Foundation Ospedale Maggiore Policlinico; 11. Hematology Unit, AUSL- IRCCS di Reggio Emilia; 12. Hematology Unit, A. O. U. Policlinico Tor Vergata Foundation; 13. Hematology Unit, AO Città della Salute e della Scienza; 14. Hematology Unit, A. O. R. N. S. Giuseppe Moscati; 15. Hematology Unit, IRCCS Ospedale San Raffaele; 16. Hematology Unit, A. O. R. N. A. Cardarelli; 17. Hematology Unit, Ospedale S. Maria delle Croci; 18. Hematology Unit, A. O. U. S. Giovanni di Dio e Ruggi D’aragona; 19. Hematology Unit, ASST Papa Giovanni XXIII; 20. Hematology Unit, IEO European Institute of Oncology; 21. Stem Cell Transplantation Unit, AOR Villa Sofia-Cervello; 22. DIMEC Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna